Bronchogen
Evidence: D+/C-Experimental / Early Research
Evidence Snapshot
Regulatory Context
Do not present Bronchogen as an approved respiratory medicine.
Research Takeaway
Bronchogen is an ultrashort synthetic peptide from the Khavinson bioregulator program, canonically sequenced as Ala-Glu-Asp-Leu (AEDL). One source (PMID 21240358) states the residue order as Ala-Asp-Glu-Leu in its own title -- this is a documented source inconsistency, not the canonical sequence; three later papers from the same research lineage converge on AEDL.
Evidence boundary: The exact reason for the PMID 21240358 title discrepancy could not be determined from the accessible record; it is most likely a title/indexing/transliteration inconsistency. Separately, one of this claim's three citations (PMID 28371610) is a cross-species tobacco-plant (Nicotiana tabacum) gene-expression study, included only as sequence/naming corroboration -- it is NOT evidence for a mammalian respiratory mechanism, NOT evidence for human pulmonary efficacy, and must not be used to strengthen any respiratory therapeutic claim.
See all 6 evidence claims →Quick Summary
Bronchogen is an ultrashort synthetic peptide from the Khavinson bioregulator program, canonically sequenced as Ala-Glu-Asp-Leu (AEDL). It has been studied in DNA-interaction, gene-expression, and pulmonary preclinical models; no robust modern human efficacy program has been identified.
Mechanism & Research Overview
Laboratory studies report DNA interaction/stabilization and gene-expression effects for Bronchogen.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Bronchogen is an ultrashort synthetic peptide from the Khavinson bioregulator program, canonically sequenced as Ala-Glu-Asp-Leu (AEDL). One source (PMID 21240358) states the residue order as Ala-Asp-Glu-Leu in its own title -- this is a documented source inconsistency, not the canonical sequence; three later papers from the same research lineage converge on AEDL.
Does not establish
Evidence boundary: The exact reason for the PMID 21240358 title discrepancy could not be determined from the accessible record; it is most likely a title/indexing/transliteration inconsistency. Separately, one of this claim's three citations (PMID 28371610) is a cross-species tobacco-plant (Nicotiana tabacum) gene-expression study, included only as sequence/naming corroboration -- it is NOT evidence for a mammalian respiratory mechanism, NOT evidence for human pulmonary efficacy, and must not be used to strengthen any respiratory therapeutic claim.
Sources: Effect of the peptide bronchogen on DNA thermal stability; KED/Vesugen and Tissue-Specific Cell Differentiation; Short Exogenous Peptides Regulate Expression of CLE, KNOX1, and GRF Family Genes in Nicotiana tabacum
Supported
Laboratory studies report DNA interaction/stabilization and gene-expression effects for Bronchogen.
Sources: Effect of the peptide bronchogen on DNA thermal stability; Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA
Supported
Cell and animal studies report effects involving bronchial epithelium and pulmonary remodeling/inflammatory markers.
Sources: KED/Vesugen and Tissue-Specific Cell Differentiation; Bronchogen pulmonary-remodeling study; Anti-inflammatory/regenerative pulmonary study of Bronchogen
Supported
Robust modern randomized human efficacy evidence was not identified for Bronchogen.
Sources: MitoCore Batch 9 human-clinical-evidence literature search audit
Supported
Preclinical respiratory findings do not establish treatment efficacy for COPD, asthma, bronchitis, or other pulmonary disease.
Sources: KED/Vesugen and Tissue-Specific Cell Differentiation; Bronchogen pulmonary-remodeling study; Anti-inflammatory/regenerative pulmonary study of Bronchogen
Supported
Do not present Bronchogen as an approved respiratory medicine.
Sources: MitoCore Batch 9 regulatory search: FDA approval status and ClinicalTrials.gov registration check
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
PMID 21240358's own title states Ala-Asp-Glu-Leu, conflicting with the AEDL order used elsewhere in the lineage. Retained as a documented inconsistency.Safety Consideration
Preclinical respiratory findings do not establish treatment efficacy for COPD, asthma, bronchitis, or other pulmonary disease.Safety Consideration
A substantial portion of the Bronchogen literature comes from overlapping investigators and institutions within the Khavinson/St. Petersburg bioregulator research program. This concentration limits independent replication and generalizability; repeated publications from the same research lineage should not be interpreted as equivalent to independent multicenter replication.
Research Areas Being Studied
Research areas discussed on this page reflect the Experimental / Early Research category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
No Human Study Findings Listed Yet
See preclinical, regulatory, and review sources below.
Study Tables by Evidence Type
Human Studies & Clinical Data
No Human Studies & Clinical Data Listed Yet
This section will be updated as sources are added.
Animal / Cell / Preclinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA | 2011 | The study included fluorescently labeled Pinealon (Glu-Asp-Arg) and reported cellular or nuclear penetration and interactions with nucleic-acid targets in vitro. | |||
| Anti-inflammatory/regenerative pulmonary study of Bronchogen | Reports anti-inflammatory and regenerative pulmonary markers associated with Bronchogen in an animal model. | ||||
| Bronchogen pulmonary-remodeling study | Animal study reporting Bronchogen effects on pulmonary remodeling measures. | ||||
| Effect of the peptide bronchogen on DNA thermal stability | Reports DNA thermal-stability effects of Bronchogen. NOTE: this paper's own title states the sequence as Ala-Asp-Glu-Leu, an outlier versus later papers in the same lineage which converge on Ala-Glu-Asp-Leu (AEDL) -- retained here as a documented source inconsistency, not the canonical sequence. | ||||
| Short Exogenous Peptides Regulate Expression of CLE, KNOX1, and GRF Family Genes in Nicotiana tabacum | A cross-species short-peptide gene-expression screen in tobacco (Nicotiana tabacum) plants that includes the AEDL/Bronchogen sequence. Useful only for sequence-naming corroboration -- this is a PLANT gene-expression study, not human or mammalian biology, and must not be cited as biological/mechanistic support for a human respiratory claim. | Cross-species (plant) study; not applicable to human safety or mechanism claims. |
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| MitoCore Batch 9 regulatory search: FDA approval status and ClinicalTrials.gov registration check | 2026 | Direct search performed 2026-08-17 for FDA drug-approval status and ClinicalTrials.gov interventional-trial registration for PNC-27, Pancragen, Bronchogen, Testagen, Chonluten, Prostamax, Ovagen, and N-Acetyl Epitalon Amidate (Ac-AEDG-NH2), including known aliases and sequence names. No FDA-approved drug product was identified for any of the eight compounds. No registered ClinicalTrials.gov interventional trial was identified for any of the eight compounds. All eight are marketed exclusively through peptide/research-chemical vendors as research-use-only products, not as approved medicines. Absence from these searches is not itself a formal FDA determination and does not establish safety or ineffectiveness -- it establishes only that no approval or registered trial was located in this search pass. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Content pending review. Last updated 2026-08-17.
Follow research updates for Bronchogen
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.